{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Data was not collected","groups":[{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"populationDescription":"Pharmacokinetic population","reportingStatus":"POSTED","timeFrame":"Day 1, 8, 15 and 22","title":"Maximum Observed Concentration (Cmax) of Azacitidine and Durvalumab","type":"SECONDARY"}